Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two cholesterol drugs better than one? new study investigates

NCT ID NCT07313124

Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial looked at whether taking two cholesterol-lowering drugs (rosuvastatin and ezetimibe) is more effective and safer than taking just one (rosuvastatin) for people with heart disease. 66 adults with high cholesterol were randomly assigned to one of the two treatments and followed for up to 12 weeks. The study measured changes in cholesterol levels and checked for muscle-related side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rosuvastatin and ezetimibe
What this could lead to
If successful, this could show that a combination of two cholesterol-lowering drugs works better than one alone for heart disease patients.
What could go wrong
This is a small, completed trial with only 66 participants, so results may not apply to everyone. It also focuses on lab tests, not long-term heart outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

66 people

The number who actually took part.

Started

Dec 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults above 18 years, Dyslipidemic patients Exclusion Criteria: Young people under 18 years old pregnant women lactating women Children Hypersensitivity Renal failure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases (CVD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases (CVD)

Contacts and locations

Locations

  • Beni-Suef University Hospital

    Banī Suwayf, Beni Suweif Governorate, 62521, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.